



BioInvent receives notice of allowance from U.S. Patent and Trademark Office relevant to its F.I.R.S.T.[™] platform

Lund, Sweden – 26 September 2018 – BioInvent International AB (OMXS: BINV) announces today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance, informing the company that a patent application relevant to its unique, function-based F.I.R.S.T.[™] platform now can proceed to be granted.

The patent application relates to combined use of differential biopanning and next generation sequencing, NGS, in identification of antibodies to differentially expressed cell surface antigens. The patent is expected to be granted once BioInvent has responded to the USPTO's notice.

Corresponding patents have already been granted by the European Patent Office (EPO) and in Australia, Japan and Russia. The company has similar patent applications pending in further countries.

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program BI-1206 is currently in a Phase 1/2 for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.se

For further information, please contact:

Martin Welschhof, CEO
+46 (0)46 286 85 50
martin.welschhof@bioinvent.com

Hans Herklots, LifeSci Advisors
+41 79 598 71 49
hherklots@lifesciadvisors.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.se

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.20 a.m. CET, on 26 September, 2018.

